• Hexboare [they/them]@hexbear.net
    link
    fedilink
    English
    arrow-up
    6
    ·
    1 month ago

    I understand that the dosages of semaglutide for diabetes range from 0.25mg to 2mg - are you saying people are injecting 10mg a week? That does seem like a considerable leap

    Th lifetime usage aspect makes them particularly attractive for pharma companies

    • xiaohongshu [none/use name]@hexbear.net
      link
      fedilink
      English
      arrow-up
      3
      ·
      edit-2
      1 month ago

      All SUSTAIN trials were performed at 0.5mg or 1.0mg, where glycemic control was largely achieved with 0.5mg dose, except for severe patients where lower dosage was inadequate to reach the HbA1c target.

      STEP trials for weight loss were done with 2.4mg per week, which is 5 times the dosage normally prescribed for Type 2 diabetes patients.

      • Hexboare [they/them]@hexbear.net
        link
        fedilink
        English
        arrow-up
        2
        ·
        1 month ago

        Yeah they did another trial (SUSTAIN FORTE) for diabetes after those

        Semaglutide is an effective treatment for type 2 diabetes; however, 20–30% of patients given semaglutide 1·0 mg do not reach glycaemic treatment goals. We aimed to investigate the efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in adults with inadequately controlled type 2 diabetes

        10.1016/S2213-8587(21)00174-1

        • xiaohongshu [none/use name]@hexbear.net
          link
          fedilink
          English
          arrow-up
          2
          ·
          edit-2
          1 month ago

          Yes, one trial in the last 5 years. Which is why I said we’re nowhere close to knowing the long term effect of these dosage. The first SUSTAIN goes back to 2014 and we have about a decade of data. All the STEP trials are within 5 years.

          You should also note that going from 1.0mg to 2.0mg (doubling the dosage) improved the HbA1c measure from 1.9% reduction to 2.1%. It’s statistically significant but the effect is also small (an improvement for treating severe patients but not so much for the rest of the disease population). Most of the reduction is in the body weight when increasing the dosage.

          • Hexboare [they/them]@hexbear.net
            link
            fedilink
            English
            arrow-up
            1
            ·
            1 month ago

            Right, but the weight loss increase was also very small

            Mean change in bodyweight from baseline at week 40 was −6·9 kg with semaglutide 2·0 mg and −6·0 kg with semaglutide 1·0 mg

            So glycated haemoglobin improves by 10 percent and weight loss increase by 15 percent.

            This would suggest to me that whatever long term problems are associated with semaglutide at 2mg are probably going to be associated with semaglutide at 1mg at broadly similar rates.

            Time will tell though!